Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment

Here we report three cases of anti-myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) mimicking multiple sclerosis in which seropositivity for anti-MOG antibodies occurred during disease-modifying drug dimethyl fumarate (DMF) treatment. These patients developed relapses wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Keita, Takeuchi, Hideyuki, Fukai, Ryoko, Nakamura, Haruko, Morihara, Keisuke, Higashiyama, Yuichi, Takahashi, Toshiyuki, Doi, Hiroshi, Tanaka, Fumiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917254/
https://www.ncbi.nlm.nih.gov/pubmed/33659007
http://dx.doi.org/10.3389/fimmu.2021.625465
_version_ 1783657659086405632
author Takahashi, Keita
Takeuchi, Hideyuki
Fukai, Ryoko
Nakamura, Haruko
Morihara, Keisuke
Higashiyama, Yuichi
Takahashi, Toshiyuki
Doi, Hiroshi
Tanaka, Fumiaki
author_facet Takahashi, Keita
Takeuchi, Hideyuki
Fukai, Ryoko
Nakamura, Haruko
Morihara, Keisuke
Higashiyama, Yuichi
Takahashi, Toshiyuki
Doi, Hiroshi
Tanaka, Fumiaki
author_sort Takahashi, Keita
collection PubMed
description Here we report three cases of anti-myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) mimicking multiple sclerosis in which seropositivity for anti-MOG antibodies occurred during disease-modifying drug dimethyl fumarate (DMF) treatment. These patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery. MOGAD is considered a humoral immune disease, and DMF reportedly enhances Th2-skewed humoral immune activity. Therefore, we suggest that DMF, but not fingolimod, may exacerbate humoral immune imbalance and enhance autoantibody production, leading to aggravation of MOGAD.
format Online
Article
Text
id pubmed-7917254
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79172542021-03-02 Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment Takahashi, Keita Takeuchi, Hideyuki Fukai, Ryoko Nakamura, Haruko Morihara, Keisuke Higashiyama, Yuichi Takahashi, Toshiyuki Doi, Hiroshi Tanaka, Fumiaki Front Immunol Immunology Here we report three cases of anti-myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) mimicking multiple sclerosis in which seropositivity for anti-MOG antibodies occurred during disease-modifying drug dimethyl fumarate (DMF) treatment. These patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery. MOGAD is considered a humoral immune disease, and DMF reportedly enhances Th2-skewed humoral immune activity. Therefore, we suggest that DMF, but not fingolimod, may exacerbate humoral immune imbalance and enhance autoantibody production, leading to aggravation of MOGAD. Frontiers Media S.A. 2021-02-15 /pmc/articles/PMC7917254/ /pubmed/33659007 http://dx.doi.org/10.3389/fimmu.2021.625465 Text en Copyright © 2021 Takahashi, Takeuchi, Fukai, Nakamura, Morihara, Higashiyama, Takahashi, Doi and Tanaka. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Takahashi, Keita
Takeuchi, Hideyuki
Fukai, Ryoko
Nakamura, Haruko
Morihara, Keisuke
Higashiyama, Yuichi
Takahashi, Toshiyuki
Doi, Hiroshi
Tanaka, Fumiaki
Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment
title Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment
title_full Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment
title_fullStr Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment
title_full_unstemmed Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment
title_short Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment
title_sort case report: anti-mog antibody seroconversion accompanied by dimethyl fumarate treatment
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917254/
https://www.ncbi.nlm.nih.gov/pubmed/33659007
http://dx.doi.org/10.3389/fimmu.2021.625465
work_keys_str_mv AT takahashikeita casereportantimogantibodyseroconversionaccompaniedbydimethylfumaratetreatment
AT takeuchihideyuki casereportantimogantibodyseroconversionaccompaniedbydimethylfumaratetreatment
AT fukairyoko casereportantimogantibodyseroconversionaccompaniedbydimethylfumaratetreatment
AT nakamuraharuko casereportantimogantibodyseroconversionaccompaniedbydimethylfumaratetreatment
AT moriharakeisuke casereportantimogantibodyseroconversionaccompaniedbydimethylfumaratetreatment
AT higashiyamayuichi casereportantimogantibodyseroconversionaccompaniedbydimethylfumaratetreatment
AT takahashitoshiyuki casereportantimogantibodyseroconversionaccompaniedbydimethylfumaratetreatment
AT doihiroshi casereportantimogantibodyseroconversionaccompaniedbydimethylfumaratetreatment
AT tanakafumiaki casereportantimogantibodyseroconversionaccompaniedbydimethylfumaratetreatment

Ejemplares similares